title: Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology.
abstract: OBJECTIVE
  To determine the correspondence of in vivo quantitative estimates of brain uptake of fluorine 18-labeled flutemetamol with immunohistochemical estimates of amyloid levels in patients who underwent previous biopsy.
  
  
  METHODS
  Cross-sectional study of ¹⁸F-flutemetamol positron emission tomography (PET) findings in patients with prior cortical biopsy specimen stained for the presence or absence of amyloid plaques.
  
  
  METHODS
  University hospital. Patients Seven patients who previously had a prior right frontal cortical biopsy at the site of ventriculoperitoneal placement for presumed normal pressure hydrocephalus were recruited. Inclusion criteria included an adequate biopsy specimen for detection and quantification of β-amyloid pathology and age older than 50 years. Intervention All patients underwent an ¹⁸F-flutemetamol PET scan.
  
  
  METHODS
  Quantitative measures of ¹⁸F-flutemetamol uptake (standardized uptake value ratio, a ratio of mean target cortex activity divided by that in a cerebellar reference region) were made at a location contralateral to the biopsy site and compared with estimates of amyloid load based on immunohistochemical and histological staining.
  
  
  RESULTS
  There was complete agreement between visual reads of ¹⁸F-flutemetamol PET scans (3 blinded readers with majority rule) and histology. A regression model, including time from biopsy as a covariate, demonstrated a significant relationship (P = .01) between ¹⁸F-flutemetamol uptake and percentage of area of amyloid measured by a monoclonal antibody raised against amyloid (NAB228). Similar results were found with the amyloid-specific monoclonal antibody 4G8 and Thioflavin S.
  
  
  CONCLUSIONS
  To our knowledge, these data are the first to demonstrate the concordance of ¹⁸F-flutemetamol PET imaging with histopathology, supporting its sensitivity to detect amyloid and potential use in the study and detection of Alzheimer disease.
authors: Penn Memory Center, 3615 Chestnut St, Philadelphia, PA 19104, USA. david.wolk@uphs.upenn.edu
authors: David A
authors: DA
authors: Wolk
authors: Igor D
authors: ID
authors: Grachev
authors: Chris
authors: C
authors: Buckley
authors: Hala
authors: H
authors: Kazi
authors: M Sean
authors: MS
authors: Grady
authors: John Q
authors: JQ
authors: Trojanowski
authors: Roy H
authors: RH
authors: Hamilton
authors: Paul
authors: P
authors: Sherwin
authors: Richard
authors: R
authors: McLain
authors: Steven E
authors: SE
authors: Arnold
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000814:Aniline Compounds; D052160:Benzothiazoles; D002540:Cerebral Cortex / Q000000981:diagnostic imaging* / Q000473:pathology*; D003430:Cross-Sectional Studies; D005260:Female; D005462:Fluorine Radioisotopes; D006801:Humans; D008297:Male; D008875:Middle Aged; D058225:Plaque, Amyloid / Q000000981:diagnostic imaging* / Q000473:pathology*; D049268:Positron-Emission Tomography / Q000379:methods; D013844:Thiazoles
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D000814:Aniline Compounds; D052160:Benzothiazoles; D005462:Fluorine Radioisotopes; D013844:Thiazoles